A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (REBUILD-SM trial)

Not Applicable

Recruiting

• Conditions: Interstitial Lung Disease; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12623001133628
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-02
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

•Physician confirmed diagnosis of interstitial lung disease (ILD)
•Able to provide informed consent
•Able to read written English or have someone reading for them in their preferred language
•Able to speak English
•Own a smartphone or tablet compatible with RE-BUILD App
•Digital literacy to be able to download and use smartphone application
•Have an email address
•On stable treatment for ILD for 1 month (no changes to ILD medications within 1 month prior to recruitment)

Exclusion Criteria

•Unable to communicate in English
•Unable to consent due to cognitive impairment or other reason
•Not on stable treatment for ILD (changes to ILD medications within the previous 1 month)
•Currently participating in pulmonary rehabilitation
•Death or transplant anticipated within the study period
•Digital illiteracy preventing download and use of apps

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in health-related quality of life will be measured by change in King's Brief Interstitial Lung Disease (K-BILD) questionnaire score.[ Baseline and 12 weeks after randomisation]